PubRank
Search
About
Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy
Clinical Trial ID NCT01029366
PubWeight™ 69.61
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01029366
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
N Engl J Med
2011
18.99
2
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Sci Transl Med
2011
12.58
3
Chimeric antigen receptor T cells for sustained remissions in leukemia.
N Engl J Med
2014
8.21
4
The basic principles of chimeric antigen receptor design.
Cancer Discov
2013
3.28
5
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
Blood
2014
2.84
6
Gene-engineered T cells for cancer therapy.
Nat Rev Cancer
2013
2.07
7
Chimeric antigen receptor therapy for cancer.
Annu Rev Med
2013
1.94
8
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Nat Rev Clin Oncol
2013
1.91
9
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
Int J Hematol
2013
1.64
10
Adoptive immunotherapy for cancer or viruses.
Annu Rev Immunol
2014
1.61
11
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
Clin Cancer Res
2012
1.37
12
Engineered T-cell therapy shows efficacy in blood cancer.
Nat Biotechnol
2011
1.17
13
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.
PLoS One
2013
1.14
14
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Discov Med
2010
0.99
15
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells.
Front Immunol
2013
0.98
16
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).
Ther Adv Hematol
2015
0.95
17
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
Clin Lymphoma Myeloma Leuk
2012
0.88
18
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
Blood
2016
0.87
19
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.
Leukemia
2014
0.86
20
Clinical development of gene therapy: results and lessons from recent successes.
Mol Ther Methods Clin Dev
2016
0.85
21
Immunotherapy for pediatric leukemia.
Front Oncol
2013
0.84
22
Synthetic biology in cell-based cancer immunotherapy.
Trends Biotechnol
2015
0.84
23
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.
ISRN Oncol
2012
0.84
24
Genetically engineered T cells for the treatment of cancer.
J Intern Med
2013
0.83
25
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Immunotherapy
2014
0.81
26
Cellular therapies in acute lymphoblastic leukemia.
Hematol Oncol Clin North Am
2011
0.78
27
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.
Expert Opin Biol Ther
2015
0.77
28
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
Hematol Oncol Clin North Am
2013
0.76
29
Toward synthetic biology with engineered T cells: a long journey just begun.
Hum Gene Ther
2014
0.75
30
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Pediatr Blood Cancer
2015
0.75
Next 100